|
|
Article: NeurAxon Series B Garners $32M For nNOS Pain Drugs.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
In one of the larger U.S.-led Series B rounds, NeurAxon Inc. raised $32 million for its approach to pain drugs that targets neuronal nitric oxide synthase (nNOS), with the lead candidate - oral NXN-188, which also is an agonist of 5-hydroxytryptamine (5-HT) - set to enter Phase IIa trials for migraine some time this quarter.
The Waltham, Mass.-based firm has enough cash to easily get into 2009, when as many as five trials could be ongoing, possibly even some Phase II studies, said CEO Lawrence Bloch. At that point, NeurAxon would consider a Series C financing, collaboration or initial public offering.
Still at the preclinical ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|